Search This Blog

Friday, November 6, 2015

Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015

Data Underscore Company's Commitment to Difficult-to-Treat Blood Cancers
New Insights Further Strengthen Evidence of the Role of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma
Growing Body of Clinical Evidence Validates Immunotherapy BLINCYTO® (Blinatumomab) for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia


Amgen - Investors - RSS Content
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)